Ocuphire Pharma Results

Summary of APX3330 Prior Clinical Trials Completed 11 Clinical Trials Across Healthy, Hepatic and Cancer Patients Ocuphire PHARMA Extensively Studied in 11 Clinical Trials across Phase 1 and Phase 2 by Eisai and Apexian Study ID APX_CLN_0001 APX_CLN_0002 APX_CLN_0003 APX_CLN_0004 APX_CLN_0008 Phase 1 Studies Phase 1 Patient Population Healthy Subjects Healthy Subjects Healthy Subjects Healthy Subjects Healthy Subjects 5 Treatment Groups APX3330, Placebo APX3330, Placebo APX3330 APX3330 APX3330, Placebo Study ID APX_CLN_0005 APX_CLN_0006 APX_CLN_0007 APX_CLN_0009 APX_CLN_0010 APX_CLN_0011 Phase 2 Studies Phase 2 Patient Population Chronic Hep Chronic Hep C Chronic Hep C Acute severe hepatitis Alcoholic hepatitis Cancer (solid tumors) 6 Treatment Groups APX3330 APX3330 APX3330, Placebo APX3330 APX3330 APX3330 37

View entire presentation